XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Fair Value Measurements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Realized gain on sale of equity securities       $ 32,139  
Estimated fair value of equity securities   $ 0   0   $ 41,937
Unrealized gain on equity securities   $ 0 $ 694 $ 0 $ 2,023  
Vaxcyte, Inc. | Vaxcyte Common Stock            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Shares of common stock, sold   667,780 0 667,780 0  
Investment, Type [Extensible Enumeration]   Equity Securities [Member] Equity Securities [Member] Equity Securities [Member] Equity Securities [Member]  
Realized gain on sale of equity securities   $ 23,700   $ 32,100    
Number of shares held   0   0   667,780
Estimated fair value of equity securities   $ 74,000   $ 74,000   $ 41,900
Blackstone Life Sciences | Royalty | 2015 License Agreement            
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]            
Revenue interest percentage 4.00%     4.00%